DOES USE OF INHALED FLUTICASONE PRIOR TO AN ADENOSINE 5'MONOPHOSPHATE (AMP) BRONCHIAL PROVOCATION TEST AFFECT THE PERCEPTION OF DYSPNOEA?

DOES USE OF INHALED FLUTICASONE PRIOR TO AN ADENOSINE 5'MONOPHOSPHATE (AMP) BRONCHIAL PROVOCATION TEST AFFECT THE PERCEPTION OF DYSPNOEA in asthmatic patients and the development of nasal symptoms?

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12605000611628

Acronym

PD-NS

Enrollment

Registered

2005-10-06

Start date

2005-10-01

Completion date

2006-10-01

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Fluticasone 250mcg inhaled 2 or 14 hours before Adenosine 5' Monophostate Bronchial provocation. Perception of Dyspnoea and Nasal symptoms developed are recorded.

Study design

Allocation

Randomised controlled trial

Intervention model

Crossover

Primary purpose

Diagnosis

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

0 to No maximum

Healthy volunteers

Inclusion criteria

Allergy to inhaled allergens. Mild asthma and rhinitis.

Exclusion criteria

No exclusion criteria

Outcome results